Streamline your COVID-19 testing and reporting...

With the BD Veritor™ Plus System* and ImageMover app

As you continue to navigate the ever-changing complexities of COVID-19, having the right tools can help you scale testing as needed and take care of people. The faster you detect a pathogen, the sooner you can respond and limit its spread. The **BD Veritor™ Plus System**, combined with the **ImageMover app**, offers you a simple, reliable and flexible HIPAA-compliant solution to fit your needs. You can be confident that you are doing all you can to move forward as safely as possible.

Designed to work with you and for you—at every step

1 Easy registration

Get started quickly by pre-loading lists of test subjects and obtaining consent

Reduce paperwork by scanning driver's licenses to pre-populate information for on-site registration

Streamline the process by printing unique barcodes for each test where needed

2 Rapid, accurate (per label) results

Minimize wait times with reliable results for SARS-CoV-2 in 15 minutes[1]

Securely capture and store test results

Expand testing with online training, easy-to-read display and single-button functionality

3 Timely reporting

Build confidence by securely providing patients with result

Stay compliant by auto-submitting daily reports to the U.S. HHS, as required[2]

Minimize manual transcription by downloading .CSV report outputs

For more information contact your local BD or distributor representative.

*The intended use of the BD Veritor™ System for Rapid Detection of SARS-CoV-2 assay only includes those who are suspected of COVID-19 by their health care provider within the first five days of the onset of symptoms.

- This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories
- This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and
- This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

References:

1. BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2. Package insert. Becton, Dickinson and Company. **2.** HHS Announces New Laboratory Data Reporting Guidance for COVID-19 Testing. U.S. Department of Health & Human Services website. https://www.hhs.gov/about/news/2020/06/04/hhs-announces-new-laboratory-data-reporting-guidance-for-covid-19-testing.html. Published June 4, 2020. Updated September 23, 2020. Accessed February 16, 2021.

BDVeritor.com